Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.03
MYL's Cash to Debt is ranked lower than
57% of the 1158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. MYL: 0.03 )
MYL' s 10-Year Cash to Debt Range
Min: 0.03   Max: 38.64
Current: 0.03

0.03
38.64
Equity to Asset 0.21
MYL's Equity to Asset is ranked lower than
52% of the 965 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. MYL: 0.21 )
MYL' s 10-Year Equity to Asset Range
Min: 0.19   Max: 0.9
Current: 0.21

0.19
0.9
Interest Coverage 4.06
MYL's Interest Coverage is ranked lower than
53% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 236.52 vs. MYL: 4.06 )
MYL' s 10-Year Interest Coverage Range
Min: 0.83   Max: 9.19
Current: 4.06

0.83
9.19
F-Score: 6
Z-Score: 2.41
M-Score: -2.41
WACC vs ROIC
6.97%
11.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.52
MYL's Operating margin (%) is ranked higher than
88% of the 1107 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.08 vs. MYL: 17.52 )
MYL' s 10-Year Operating margin (%) Range
Min: 2.31   Max: 36
Current: 17.52

2.31
36
Net-margin (%) 12.04
MYL's Net-margin (%) is ranked higher than
84% of the 1107 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.46 vs. MYL: 12.04 )
MYL' s 10-Year Net-margin (%) Range
Min: -3.53   Max: 26.04
Current: 12.04

-3.53
26.04
ROE (%) 28.88
MYL's ROE (%) is ranked higher than
94% of the 1135 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.08 vs. MYL: 28.88 )
MYL' s 10-Year ROE (%) Range
Min: -8.33   Max: 29.99
Current: 28.88

-8.33
29.99
ROA (%) 6.01
MYL's ROA (%) is ranked higher than
78% of the 1169 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.54 vs. MYL: 6.01 )
MYL' s 10-Year ROA (%) Range
Min: -2.47   Max: 18.43
Current: 6.01

-2.47
18.43
ROC (Joel Greenblatt) (%) 31.12
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 1164 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.30 vs. MYL: 31.12 )
MYL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.11   Max: 92.62
Current: 31.12

4.11
92.62
Revenue Growth (3Y)(%) 11.60
MYL's Revenue Growth (3Y)(%) is ranked higher than
80% of the 948 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. MYL: 11.60 )
MYL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -6.1   Max: 54.5
Current: 11.6

-6.1
54.5
EBITDA Growth (3Y)(%) 11.30
MYL's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 846 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. MYL: 11.30 )
MYL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20   Max: 107
Current: 11.3

-20
107
EPS Growth (3Y)(%) 24.20
MYL's EPS Growth (3Y)(%) is ranked higher than
88% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.10 vs. MYL: 24.20 )
MYL' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.8   Max: 110.4
Current: 24.2

-28.8
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MYL Guru Trades in Q1 2014

Andreas Halvorsen 1,776,108 sh (New)
Paul Tudor Jones 432,717 sh (New)
Louis Moore Bacon 134,160 sh (New)
Jean-Marie Eveillard 675,428 sh (New)
Jim Simons 1,401,474 sh (New)
Steven Cohen 553,164 sh (+6.49%)
Mario Gabelli 13,000 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
David Dreman Sold Out
Joel Greenblatt Sold Out
John Paulson 12,130,700 sh (-0.07%)
Scott Black 274,571 sh (-10.63%)
John Hussman 50,000 sh (-75.00%)
» More
Q2 2014

MYL Guru Trades in Q2 2014

Pioneer Investments 226,453 sh (New)
Jean-Marie Eveillard 1,241,991 sh (+83.88%)
Mario Gabelli 13,800 sh (+6.15%)
John Paulson 12,130,700 sh (unchged)
Steven Cohen 83,700 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
John Hussman 50,000 sh (unchged)
Andreas Halvorsen Sold Out
Louis Moore Bacon 100,000 sh (-25.46%)
Scott Black 201,925 sh (-26.46%)
Jim Simons 652,200 sh (-53.46%)
Paul Tudor Jones 4,200 sh (-99.03%)
» More
Q3 2014

MYL Guru Trades in Q3 2014

Ray Dalio 57,106 sh (New)
Paul Tudor Jones 20,015 sh (+376.55%)
Louis Moore Bacon 435,000 sh (+335.00%)
Vanguard Health Care Fund 15,444,880 sh (+223.41%)
John Paulson 12,494,700 sh (+3.00%)
Louis Moore Bacon 350,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Pioneer Investments 282,805 sh (unchged)
Steven Cohen Sold Out
Scott Black 199,406 sh (-1.25%)
Mario Gabelli 10,000 sh (-27.54%)
Jim Simons 465,200 sh (-28.67%)
Jean-Marie Eveillard 809,603 sh (-34.81%)
» More
Q4 2014

MYL Guru Trades in Q4 2014

Joel Greenblatt 673,287 sh (New)
Paul Tudor Jones 254,152 sh (+1169.81%)
Pioneer Investments 691,198 sh (+144.41%)
John Paulson 14,948,400 sh (+19.64%)
Jean-Marie Eveillard 841,779 sh (+3.97%)
Mario Gabelli 10,000 sh (unchged)
Louis Moore Bacon 200,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Jim Simons Sold Out
Vanguard Health Care Fund 15,037,080 sh (-2.64%)
Ray Dalio 52,706 sh (-7.70%)
Scott Black 181,796 sh (-8.83%)
Louis Moore Bacon 36,196 sh (-91.68%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Mylan NV

Vanguard Health Care Fund Comments on Mylan NV - Mar 27, 2015

We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Mylan NV

Vanguard Health Care Fund Comments on Mylan NV
We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 32.60
MYL's P/E(ttm) is ranked higher than
82% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 60.40 vs. MYL: 32.60 )
MYL' s 10-Year P/E(ttm) Range
Min: 7.05   Max: 112.56
Current: 32.6

7.05
112.56
Forward P/E 15.75
MYL's Forward P/E is ranked higher than
94% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 15.75 )
N/A
PE(NRI) 29.10
MYL's PE(NRI) is ranked higher than
85% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 59.00 vs. MYL: 29.10 )
MYL' s 10-Year PE(NRI) Range
Min: 7.05   Max: 200.11
Current: 29.1

7.05
200.11
P/B 8.80
MYL's P/B is ranked higher than
50% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.20 vs. MYL: 8.80 )
MYL' s 10-Year P/B Range
Min: 0.64   Max: 8.8
Current: 8.8

0.64
8.8
P/S 4.00
MYL's P/S is ranked higher than
68% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.25 vs. MYL: 4.00 )
MYL' s 10-Year P/S Range
Min: 0.41   Max: 4.61
Current: 4

0.41
4.61
PFCF 115.20
MYL's PFCF is ranked higher than
74% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 115.20 )
MYL' s 10-Year PFCF Range
Min: 8.81   Max: 115.2
Current: 115.2

8.81
115.2
POCF 26.58
MYL's POCF is ranked higher than
82% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.00 vs. MYL: 26.58 )
MYL' s 10-Year POCF Range
Min: 6.09   Max: 40.56
Current: 26.58

6.09
40.56
EV-to-EBIT 25.20
MYL's EV-to-EBIT is ranked higher than
82% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.18 vs. MYL: 25.20 )
MYL' s 10-Year EV-to-EBIT Range
Min: -10.7   Max: 28.8
Current: 25.2

-10.7
28.8
PEG 3.51
MYL's PEG is ranked higher than
89% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 3.51 )
MYL' s 10-Year PEG Range
Min: 0.37   Max: 11.64
Current: 3.51

0.37
11.64
Shiller P/E 58.30
MYL's Shiller P/E is ranked higher than
79% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 58.30 )
MYL' s 10-Year Shiller P/E Range
Min: 10.98   Max: 701
Current: 58.3

10.98
701
Current Ratio 1.28
MYL's Current Ratio is ranked higher than
55% of the 1028 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.23 vs. MYL: 1.28 )
MYL' s 10-Year Current Ratio Range
Min: 1.28   Max: 7.82
Current: 1.28

1.28
7.82
Quick Ratio 0.97
MYL's Quick Ratio is ranked higher than
57% of the 1028 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. MYL: 0.97 )
MYL' s 10-Year Quick Ratio Range
Min: 0.85   Max: 6.16
Current: 0.97

0.85
6.16
Days Inventory 148.81
MYL's Days Inventory is ranked higher than
68% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 141.66 vs. MYL: 148.81 )
MYL' s 10-Year Days Inventory Range
Min: 88.95   Max: 175.9
Current: 148.81

88.95
175.9
Days Sales Outstanding 107.26
MYL's Days Sales Outstanding is ranked higher than
66% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.68 vs. MYL: 107.26 )
MYL' s 10-Year Days Sales Outstanding Range
Min: 49.61   Max: 107.26
Current: 107.26

49.61
107.26

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 3.40
MYL's Price/DCF (Projected) is ranked higher than
86% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 3.40 )
MYL' s 10-Year Price/DCF (Projected) Range
Min: 0.62   Max: 2.53
Current: 3.4

0.62
2.53
Price/Median PS Value 2.10
MYL's Price/Median PS Value is ranked higher than
62% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. MYL: 2.10 )
MYL' s 10-Year Price/Median PS Value Range
Min: 0.36   Max: 3.51
Current: 2.1

0.36
3.51
Price/Peter Lynch Fair Value 3.30
MYL's Price/Peter Lynch Fair Value is ranked higher than
91% of the 1283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MYL: 3.30 )
MYL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.75   Max: 4.43
Current: 3.3

0.75
4.43
Earnings Yield (Greenblatt) 3.70
MYL's Earnings Yield (Greenblatt) is ranked higher than
78% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MYL: 3.70 )
MYL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.5   Max: 15.1
Current: 3.7

3.5
15.1
Forward Rate of Return (Yacktman) 11.89
MYL's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.49 vs. MYL: 11.89 )
MYL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.6   Max: 39.2
Current: 11.89

3.6
39.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:6MY.Germany, MYL1.Switzerland, 0R5P.UK,
Mylan NV was incorporated in Pennsylvania in 1970. The Company together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company offers 1,300 marketed products, to customers in 140 countries and territories. It also operates a research and development network that delivers a robust product pipeline. Additionally, the Company has a specialty business that is engaged in the respiratory and allergy therapies. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids while engaging on those products that are difficult to formulate and manufacture, and typically have longer life cycles than traditional generic pharmaceuticals, including transdermal patches, high potency formulations, injectables, controlled-release and respiratory products. In addition, it offers antiretroviral therapies upon which HIV/AIDS patients in developing countries depend. The Company operates in two segments, Generics and Specialty. The generic pharmaceutical business is conducted in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages in the development, manufacture and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and have also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.
» More Articles for MYL

Headlines

Articles On GuruFocus.com
Teva Eyeing Mylan For $40 Billion Apr 23 2015 
CalAmp and Illumina Significant Earnings Growth; Perrigo Rebuffs Takeover Offer Apr 22 2015 
Vanguard Health Care Fund Comments on Mylan NV Mar 27 2015 
Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
Gilead Taking Giant Leap To Serve The Hepatitis C Market Of Developing Countries Feb 26 2015 
John Paulson's Top Buys Feb 21 2015 
Weekly CFO Sells Highlight: Sherwin-Williams Co, Facebook Inc, Mylan Inc. Feb 08 2015 
Weekly CEO Sells Highlight: Family Dollar Stores Inc, Texas Instruments Inc, Mylan Inc, and PerkinEl Feb 08 2015 
Weekly Insider Sells Highlight: MYL, QRVO, HON, JBHT Feb 08 2015 


More From Other Websites
Mylan 'Raises' Perrigo Bid, But Teva Buzz Builds Apr 24 2015
Mylan makes official bid for Perrigo in generic drug contest Apr 24 2015
Mylan makes official bid for Perrigo in generic drug contest Apr 24 2015
Mylan Inc. -- Moody's: Mylan's Offer for Perrigo Credit Negative but Could be Investment Grade Apr 24 2015
Raised Bid in Three-Way Generic Drug Takeover Battle Apr 24 2015
Techs surge on earnings, boosts Nasdaq, S&P 500 to record close Apr 24 2015
Perrigo (PRGO) Stock Declines Today After Rejecting Second Mylan Bid This Week Apr 24 2015
Deutsche Bank Boosts Mylan's Price Target On This Scenario Apr 24 2015
Big pharma mergers: Mylan boosts offer for Perrigo Apr 24 2015
Mylan/Perrigo, a more likely combination: Pro Apr 24 2015
Will a Mylan 'Stichting' Become a Sticking Point for a Teva Deal? Apr 24 2015
Teva, Mylan and Perrigo: Which Combination is Most Likely? Apr 24 2015
Generic drugmaker Mylan goes hostile in bid for Perrigo Apr 24 2015
Perrigo rejects formal Mylan takeover offer Apr 24 2015
$32B deal: Mylan boosts offer for drugmaker Perrigo Apr 24 2015
Offer Rejection Apr 24 2015
Perrigo Rejects Mylan Unsolicited Offer Apr 24 2015
Perrigo Plans to Reject Mylan Takeover Offer Apr 24 2015
Perrigo Rejects Mylan Unsolicited Offer Apr 24 2015
Mylan tries to fend off Teva with bigger bid for Perrigo Apr 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK